AIIB, Gavi to provide health financing in lower-income countries
Geneva: The Asian Infrastructure Investment Bank (AIIB) and the Vaccine Alliance Gavi have signed a partnership to provide sustainable financing for health and immunization systems in low- and lower-middle-income countries.
The agreement was signed by AIIB President Jin Liqun and Gavi CEO Dr. Sania Nishta.
The two organizations intend to work on joint financing initiatives aimed at improving health outcomes and supporting
long-term financial sustainability
.
As part of the agreement, AIIB intends to provide up to USD 1 billion in financing for
public-sector health projects
. The financing will support vaccine procurement and the introduction of high-impact vaccines in middle-income countries. It will also provide targeted assistance to countries that are transitioning out of Gavi support.
The partnership also intends to explore additional financing models, including donor liquidity tools and blended financing.
The partnership is also indicated to collaborate on knowledge-sharing efforts, particularly on the intersection of climate finance, immunization, and health systems.
'Investing in human health is investing in our future – it lays the foundation for stronger communities, more resilient livelihoods and lasting prosperity,' AIIB's Jin said.
'With the threat of infectious diseases on the rise, ensuring sustainable financing for countries' efforts to build resilient immunization and health systems has never been more important for our collective health and security,' Gavi's Nishtar said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
an hour ago
- Fashion Value Chain
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Dr. Ramkesh Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages Indias CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information
Indian Express
a day ago
- Indian Express
As ‘Turkish Hairlines' meme goes viral, here's a closer look at India's troubled hair transplant industry
Hair transplant procedures are often touted as minimally invasive and largely painless. The technology or 'treatment' has been around in India for some time now, but a string of recent cases has exposed the cracks in the country's booming yet dangerously under-regulated hair transplant industry. Within 24 hours of undergoing a hair transplant at a private clinic in Kanpur, Uttar Pradesh, two engineers lost their lives. The doctor disappeared, and the clinic was sealed. In another case, two men reportedly died after a dentist – yes, a dentist – performed the procedure. A separate incident in Kerala left a patient with necrotizing fasciitis, a rare flesh-eating bacterial infection, following surgery allegedly conducted by someone with a fake medical degree. Amid rising reports of botched surgeries, growing medical tourism, and mounting social media pressure, more Indians are flying to Turkey, the unofficial global capital of hair restoration, for transplants that promise natural-looking results, often at lower costs. That's also how the viral 'Turkish Hairlines' meme was born: a video showing a plane full of bald men en route to Istanbul, all in search of hair and hope. spoke to industry experts to understand what's driving this trend and how Turkey became the global epicenter of this follicular phenomenon. According to Dr Katheeja Nasika, consultant in the department of dermatology at Rela Hospital, Chennai, the rush for perfect hairlines is driven by a mix of peer pressure, the impact of influencer marketing, and societal expectations, especially among men prepping for marriage or public life. Dr Veena Praveen, head dermatologist (South), Kaya Limited, agreed but attributed the increasing popularity to technological advancements and a rise in awareness. 'People want long-term, natural-looking solutions. For many, it's not about improving appearance alone; it's about regaining confidence,' she said. Social media and celebrity endorsements have also significantly contributed to making hair restoration more accessible and widely accepted. Shradha Rajani Mordani, CEO of Tejco Global LLP, said that the hair transplant industry is set to explode – from USD 7.3 billion in 2025 to USD 49.9 billion by 2035, growing at a CAGR of 20 per cent. 'At the heart of this surge is the new buzzword – precision technology – delivering perfected hairlines where science meets style and confidence,' she said. Mordani believes that the COVID-19 pandemic accelerated self-image anxieties. 'Video calls made people hyper-aware of their appearance. Combine that with a growing acceptance of grooming among men, and we saw a sharp rise in demand for aesthetic procedures,' she said. And it's not just hair. From micro needling to laser hair removal and PRP therapy, Indians are embracing cosmetic enhancement, but not always safely, said Dr Praveen. A post shared by Life is Beautiful (@lifeisbeautiful080808) Turkey offers advanced techniques like Follicular Unit Extraction (FUE), skilled practitioners, and all-inclusive packages – flight, stay, surgery, recovery – at competitive prices, said Dr Nasika. Dr Praveen said, 'The country has built an impressive reputation for hair restoration, combining medical excellence with cost-effective services.' 'Turkey also has a bunch of trained professionals and certified programs, which interest youngsters to pursue hair transplantation courses,' Dr Nasika said, pointing out that while India has affordable transplant options, 'the number of well-trained, ethical practitioners here is far fewer than in Turkey.' That is why Aditya Awasthee, a private investor and realtor with the Nexus Group, had been exploring the idea of getting a hair transplant and after consulting several cosmetologists and fashion industry experts, zeroed in on Turkey as the best option — even if not the most cost-efficient one. 'Turkey also has some internationally trained doctors and uses modern techniques like FUE (Follicular Unit Extraction) and DHI (Direct Hair Implantation). It's more like medical tourism, with a focus on hair restoration,' said Awasthee. His research led him towards 'highly acclaimed and established clinics offering packages that include airport transfers, hotel stay for 3–4 nights, translator services as well as medication and an aftercare kit.' Having learned about promising results and sustainable outcomes, Awasthee derived that Turkey has the highest success rate. 'Typically, Istanbul and other cities have a reputation for delivering natural-looking results,' he said, revealing that to be his primary goal. According to him, the cherry on the cake is that 'Turkey also permits combining treatment with a vacation — which allows to explore Istanbul, Cappadocia, Antalya before or after the surgery.' Dr Nasika urged people to check if the doctor is certified and the clinic or hospital has a commendable reputation before getting the procedure done. 'According to the National Medical Commission (NMC), only plastic surgeons or dermatologists are authorised to perform hair transplants in India,' she said. Money is also an important factor to consider. 'A cheap fix could lead to complications that cost far more to treat later,' Dr Nasika said. Experts say yes, but not without reforms. While Turkey is an appealing option, India also has a rich medical heritage and boasts world-class dermatologists and hair restoration experts. 'India already has world-class doctors and infrastructure,' said Dr Praveen. 'But the focus now needs to be on transparent practices, credible patient testimonials, competitive pricing, and the highest standard of post-op care. That's how trust is built,' she said. Mordani, too, said that Indian cosmetology is rapidly evolving and making it big. 'Millennials and Gen Z are pushing the demand. High-quality hair transplant instruments and devices, resulting in 'real no-downtime' results, are paving the way for a growing international doctor-clientele base adopting our technology, bringing India on the global footprint for hair restoration,' she said. According to Mordani, India's aesthetic industry is poised to lead globally by collaborating with international experts. With these advancements, Indian clinics can offer world-class treatments while meeting the growing demand for effective and accessible aesthetic solutions.
Time of India
a day ago
- Time of India
L'Oreal buys British skincare brand Medik8
L'Oreal is to acquire British skincare brand Medik8 , its owner, Britain-based private equity firm Inflexion, said on Monday, boosting the French cosmetics giant's offering in the fast-growing dermatological skincare market . The size of the deal was not disclosed. Medik8 focuses on vitamin A-based anti-ageing creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe, La Roche-Posay, and SkinCeuticals, has been its fastest growing in recent years, reaching revenues of 7 billion euros (USD 7.99 billion) last year, after growing almost 10% on the year before. The business, which also has the highest profit margin among its four divisions, has boomed on growing consumer interest in science-backed products, though growth has slowed recently due to rising competition. L'Oreal executives said this year they were pursuing acquisitions and looking to revive flagging growth. The company acquired Korean skincare brand, Dr.G, in December and also bought a minority stake in Oman-based perfume house Amourage last year.
